1
|
Shaw JE, Sicree RA and Zimmet PZ: Global
estimates of the prevalence of diabetes for 2010 and 2030. Diabetes
Res Clin Pract. 87:4–14. 2010. View Article : Google Scholar
|
2
|
Caprio S: 8th annual world congress on
insulin resistance, diabetes, and cardiovascular disease, November
4–6, 2010. Pediatr Endocrinol Rev. 8:400–402. 2011.PubMed/NCBI
|
3
|
Eyre H, Kahn R, Robertson RM, et al:
American Cancer Society, the American Diabetes Association, and the
American Heart Association Collaborative Writing Committee:
Preventing cancer, cardiovascular disease, and diabetes: a common
agenda for the American Cancer Society, the American Diabetes
Association, and the American Heart Association. Diabetes Care.
27:1812–1824. 2004. View Article : Google Scholar : PubMed/NCBI
|
4
|
Rizza S, Muniyappa R, Iantorno M, et al:
Citrus polyphenol hesperidin stimulates production of nitric oxide
in endothelial cells while improving endothelial function and
reducing inflammatory markers in patients with metabolic syndrome.
J Clin Endocrinol Metab. 96:E782–E792. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Brunner EJ, Kivimäki M, Witte DR, et al:
Inflammation, insulin resistance, and diabetes - Mendelian
randomization using CRP haplotypes points upstream. PLoS Med.
5:e1552008. View Article : Google Scholar
|
6
|
Siednienko J, Nowak J, Moynagh PN and
Gorczyca WA: Nitric oxide affects IL-6 expression in human
peripheral blood mononuclear cells involving cGMP-dependent
modulation of NF-KB activity. Cytokine. 54:282–288. 2011.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Kataoka Y, Shao M, Wolski K, et al:
Multiple risk factor intervention and progression of coronary
atherosclerosis in patients with type 2 diabetes mellitus. Eur J
Prev Cardiol. 20:209–217. 2013. View Article : Google Scholar
|
8
|
Li XM, Li Y, Zhang NN, Xie YH and Shi YQ:
Combination therapy with metformin and fenofibrate for insulin
resistance in obesity. J Int Med Res. 39:1876–1882. 2011.
View Article : Google Scholar : PubMed/NCBI
|
9
|
No authors listed. Preliminary criteria
for the classification of systemic sclerosis (scleroderma).
Subcommittee for scleroderma criteria of the American Rheumatism
Association Diagnostic and Therapeutic Criteria Committee.
Arthritis Rheum. 23:581–590. 1980. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kadoglou NP, Tsanikidis H, Kapelouzou A,
et al: Effects of rosiglitazone and metformin treatment on apelin,
visfatin, and ghrelin levels in patients with type 2 diabetes
mellitus. Metabolism. 59:373–379. 2010. View Article : Google Scholar
|
11
|
Pansuria M, Xi H, Li L, Yang XF and Wang
H: Insulin resistance, metabolic stress, and atherosclerosis. Front
Biosci (Schol Ed). 4:916–931. 2012. View
Article : Google Scholar
|
12
|
Versari D, Daghini E, Virdis A, et al:
Endothelial dysfunction as a target for prevention of
cardiovascular disease. Diabetes Care. 32(Suppl 2): S314–S321.
2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Matsumoto T, Noguchi E, Ishida K,
Kobayashi T, Yamada N and Kamata K: Metformin normalizes
endothelial function by suppressing vasoconstrictor prostanoids in
mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am
J Physiol Heart Circ Physiol. 295:H1165–H1176. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Zeng G, Nystrom FH, Ravichandran LV, et
al: Roles for insulin receptor, PI3-kinase, and Akt in
insulin-signaling pathways related to production of nitric oxide in
human vascular endothelial cells. Circulation. 101:1539–1545. 2000.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Li JL, Yang Z, Wu S and Kong J:
Relationship between endothelial nitric oxide synthase, insulin
resistance and macrovascular disease in patients with acute
myocardial infarction. J Int Med Res. 40:687–693. 2012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Tousková V and Haluzík M: Insulin
resistance and nitric oxide: molecular mechanisms and
pathophysiological associations. Cesk Fysiol. 60:40–47. 2011.(In
Czech).
|
17
|
Meaney E, Vela A, Samaniego V, et al:
Metformin, arterial function, intima-media thickness and
nitroxidation in metabolic syndrome: the mefisto study. Clin Exp
Pharmacol Physiol. 35:895–903. 2008. View Article : Google Scholar : PubMed/NCBI
|
18
|
O’Hora TR, Markos F, Wiernsperger NF and
Noble MI: Metformin causes nitric oxide-mediated dilatation in a
shorter time than insulin in the iliac artery of the anesthetized
pig. J Cardiovasc Pharmacol. 59:182–187. 2012. View Article : Google Scholar
|
19
|
Kolovou G and Giannakopoulou V:
Endothelial nitric oxide synthase gene variants and coronary heart
disease. Angiology. 63:84–85. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Malin SK, Nightingale J, Choi SE, Chipkin
SR and Braun B: Metformin modifies the exercise training effects on
risk factors for cardiovascular disease in impaired glucose
tolerant adults. Obesity (Silver Spring). 21:93–100. 2013.
View Article : Google Scholar
|